ASCO 2022 Conference Coverage

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

ASCO 2022 Conference Coverage

Breast
Lung
GI
GU
Skin
GYN
Head & Neck
Leukemia
Lymphoma
Myeloma
MDS and MPN
Sarcoma

Playback speed

10 seconds

Lecture Summary - ASCO 2022 on Elranatamab, a BCMA-Targeted T-Cell Redirecting Immunotherapy for R/R MM: Updated Results From the MagnetisMM-1 Trial

By ASCO 2022 Conference Coverage FEATURING Andrzej Jakubowiak

17 views

July 7, 2022

Comments 0

Mechanisms of Resistance in Locally Advanced or Metastatic EGFR+ NSC…

Feat. J. Heymach, M. Das

Unmet Needs for Patients With HR+, HER2- Early Breast Cancer at a Hi…

Feat. H. Rugo

Myeloma

Lecture Summary - ASCO 2022 on a Post Hoc Analysis of Sustained MRD …

ASCO 2022 Conference Coverage

C. Rodriguez

16 views

ASCO 2022 on a Post Hoc Analysis of Sustained MRD Negativity From th…

ASCO 2022 Conference Coverage

C. Rodriguez

136 views

ASCO 2022 on Elranatamab, a BCMA-Targeted T-Cell Redirecting Immunot…

ASCO 2022 Conference Coverage

A. Jakubowiak

103 views

Lecture Summary - ASCO 2022 on Elranatamab, a BCMA-Targeted T-Cell R…

ASCO 2022 Conference Coverage

A. Jakubowiak

17 views

ASCO 2022 on the Changing Landscape in Post-Transplant Treatment of …

ASCO 2022 Conference Coverage

A. Jakubowiak

75 views

Lecture Summary - ASCO 2022 Subgroup Analysis of the Phase 3 CASTOR …

ASCO 2022 Conference Coverage

A. Spencer

15 views

ASCO 2022 Subgroup Analysis of the Phase 3 CASTOR and POLLUX Studies…

ASCO 2022 Conference Coverage

A. Spencer

22 views

ASCO 2022 on Myeloma Developing Regimens Using Genomics (MyDRUG) Tri…

ASCO 2022 Conference Coverage

S. Kumar

55 views

Lecture Summary - ASCO 2022 on Myeloma Developing Regimens Using Gen…

ASCO 2022 Conference Coverage

S. Kumar

10 views

Lecture Summary - ASCO 2022 Safety and Clinical Activity of Belantam…

ASCO 2022 Conference Coverage

A. Suvannasankha

14 views

Health-Related Quality of Life in R/R MM Treated With Teclistamab, a…

Thomas Martin

773 views

ASCO 2022 Comparative Effectiveness of Teclistamab vs. Real-World Tr…

ASCO 2022 Conference Coverage

A. Krishnan

19 views

Lecture Summary - ASCO 2022 Comparative Effectiveness of Teclistamab…

ASCO 2022 Conference Coverage

A. Krishnan

14 views

Lecture Summary - ASCO 2022 Health-Related Quality of Life in R/R MM…

ASCO 2022 Conference Coverage

T. Martin

22 views

Lecture Summary - ASCO 2022 Birtamimab in Pts With Mayo Stage IV AL …

ASCO 2022 Conference Coverage

M. Gertz

259 views

ASCO 2022 Birtamimab in Pts With Mayo Stage IV AL Amyloidosis: Ratio…

ASCO 2022 Conference Coverage

M. Gertz

614 views

Lecture Summary - ASCO 2022 on B-PRISM: A Phase II Trial of Combinat…

ASCO 2022 Conference Coverage

O. Nadeem

24 views

ASCO 2022 on B-PRISM: A Phase II Trial of Combination of Daratumumab…

ASCO 2022 Conference Coverage

O. Nadeem

77 views

Lecture Summary - ASCO 2022 on the Addition of Carfilzomib as a Thir…

ASCO 2022 Conference Coverage

C. Cerchione

92 views

ASCO 2022 on the Addition of Carfilzomib as a Third Agent in Lenalid…

ASCO 2022 Conference Coverage

C. Cerchione

377 views